Rose Bengal photodynamic antimicrobial therapy as an adjunct treatment for Pseudomonas aeruginosa infectious necrotizing scleritis
Abstract
Purpose To report the utility of Rose Bengal Photodynamic Antimicrobial Therapy (RB-PDAT) as an adjunct treatment in rapidly progressing Infectious Necrotizing Scleritis (INS) secondary to Pseudomonas aeruginosa. Methods Retrospective chart review was conducted on consecutive patients with scleritis and culture-proven Pseudomonas aeruginosa who underwent RB-PDAT. Results Six patients with Pseudomonas aeruginosa INS were included. All patients achieved complete resolution of the infection. The mean time to resolution after RB-PDAT was 17 days (range; 6-30 days), with a total treatment course average of 36 days (range; 22-60 days). One patient with pan-resistant Pseudomonas sclerokeratitis required two RB-PDAT treatments due to persistent stromal melting. All patients received a standardized regimen of oral fluoroquinolone, topical tobramycin, and ciprofloxacin/moxifloxacin. The patient with pan-resistant Pseudomonas aeruginosa required treatment with topical imipenem as well. None of the patients required enucleation. Conclusion RB-PDAT is a feasible option to halt the progression of infectious necrotizing scleritis caused by Pseudomonas aeruginosa, especially in cases of impending perforation.
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.